Antidepressant “Black Box” Presents Barrier To DTC Advertising
Executive Summary
FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products
You may also be interested in...
Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)
Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)
Antidepressants To Add Class Labeling On Pregnancy & Serotonin Syndrome
Antidepressants remain at the forefront of FDA's safety focus with a pair of public health advisories on use during pregnancy and on concomitant use with triptans